Description

Thymosin Alpha 1 Peptide Vials

Introduction

Thymosin Alpha 1, a research peptide, stands at the forefront of immunomodulatory exploration. Designed exclusively for laboratory research, this peptide is crafted to investigate its impact on various facets of the immune system.

Key Characteristics

Thymosin Alpha 1 is a synthetic version of a naturally occurring thymic peptide. Renowned for its immunomodulating properties, this peptide serves as a valuable tool for researchers delving into the complexities of immune response and related pathways.

Research Applications

The primary application of Thymosin Alpha 1 in research lies in its potential to modulate the immune system. Researchers can utilize this peptide to explore its effects on immune cells, cytokine production, and overall immune function.

Research Benefits

Thymosin Alpha 1 and Cystic Fibrosis

Studies suggest that Thymosin Alpha 1 may hold promise in the context of Cystic Fibrosis (CF). Research in this area explores the peptide’s potential in addressing immune dysregulation associated with CF.

Thymosin Alpha 1 and Sepsis

Thymosin Alpha 1 has been investigated for its role in managing sepsis, a life-threatening condition resulting from a dysregulated immune response. Research indicates potential benefits in modulating immune function in septic patients.

Thymosin Alpha 1 and Lung Cancer

Exploratory research suggests a connection between Thymosin Alpha 1 and lung cancer. Investigations in this area aim to understand the peptide’s potential role in immune-mediated responses against lung cancer cells.

Summary

In summary, Thymosin Alpha 1 Peptide emerges as a focal point for immunological research. With potential benefits spanning applications in Cystic Fibrosis, sepsis management, and lung cancer studies, Thymosin Alpha 1 provides researchers with a platform to deepen our understanding of immunomodulation.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Romani, L., Oikonomou, V., Moretti, S., Iannitti, R. G., D’Adamo, M. C., Villella, V. R., Pariano, M., Sforna, L., Borghi, M., Bellet, M. M., Fallarino, F., Pallotta, M. T., Servillo, G., Ferrari, E., Puccetti, P., Kroemer, G., Pessia, M., Maiuri, L., Goldstein, A. L., & Garaci, E. (2017). Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nature Medicine, 23(5), 590-600. https://doi.org/10.1038/nm.4305. [Read More].
2. Garaci E, Lopez M, Bonsignore G, Della Giulia M, D’Aprile M, Favalli C, Rasi G, Santini S, Capomolla E, Vici P, et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer. 1995 Dec;31A(13-14):2403-5. doi: 10.1016/0959-8049(95)00477-7. PMID: 8652276. [Read More].
3. Wang FY, Fang B, Qiang XH, Yu TO, Zhong JR, Cao J, Zhou LX. The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis. Biomed Res Int. 2016;2016:9508493. doi: 10.1155/2016/9508493. Epub 2016 May 31. PMID: 27340674; PMCID: PMC4906180. [Read More].